41 India We are one of the largest private healthcare operators in India, with 27 Fortis Hospitals, six Gleneagles Hospitals and more than 400 Agilus Diagnostics laboratories under Fortis Healthcare. Our network provides a full spectrum of integrated healthcare services, including quaternary care delivered via advanced diagnostics and treatment modalities. Hospitals under IHH India are recognised as foremost experts in the fields of organ transplants, oncology, cardiology and neurosurgery. Four of our Fortis Hospitals and one of our Gleneagles Hospital India are JCI-accredited, with another 28 Fortis and Gleneagles Hospitals accredited by the National Accreditation Board for Hospitals and Healthcare Providers (NABH). Key Growth Areas • Bed expansion to meet growing demand • Improved revenue intensity from more complex cases • Enhanced services from further investments in medical equipment Performance Highlights • Strong growth in revenue intensity due to more complex treatments. • Expanded beds in the Fortis healthcare network to meet growing demand. For example, Fortis Hospital, Manesar, NCR commenced operations in September 2024. The 350-bed hospital offers a comprehensive range of clinical services ranging from cardiology and orthopaedics to neurology and oncology. • Adopted innovative medical technologies for better patient care and outcomes, such as being the first in South Asia to offer Gamma Knife Espirit at Fortis Memorial Research Institute. The single-session procedure replaces 30-plus conventional radiotherapy sessions, targeting brain tumours while protecting healthy tissue. • Celebrated the brand launch of Gleneagles Hospitals in March 2024. • Fortis and Gleneagles India jointly organised IHH Healthcare’s annual Quality Summit and Igniting Innovation in Healthcare Conference in Mumbai, where IHH’s global network of delegates discussed the future of care, focusing on clinical excellence, sustainability and patient-centered innovation. Outlook We are on a constant drive to deepen our presence within India via our twin growth engines (Fortis and Gleneagles), to make quality healthcare more accessible to underserved communities. Collectively, we aim to increase hospital bed capacity by more than a third to about 7,000 beds by 2028. We also seek expansion opportunities in existing clusters and tier-2 cities through value-accretive acquisitions, drawing strength and synergies from our large network. Ongoing investments in cutting-edge medical technologies and facility upgrades will put us in the best position to serve patients in the region seeking outstanding care and outcomes across specialties. Our expansion efforts are aligned with the national initiative of building a “Healthy India”, with medical hubs in the country being strengthened progressively. We expect a long-term growth trajectory for IHH India as well due to rising incomes, better insurance penetration and a higher rate of chronic lifestyle diseases among residents. Performance Indicators Financial FY2023 FY2024 Revenue RM3.6 billion RM4.0 billion EBITDA RM0.6 billion RM0.7 billion Operational Average Occupancy 70% 72% Inpatient admissions 299,506 313,973 Average revenue per inpatient admission RM9,154 RM9,902
RkJQdWJsaXNoZXIy NDgzMzc=